Abstract | Background: Objectives: Materials & Methods: In this retrospective study, 20 psoriasis patients with HBV infection were identified, all of whom had been treated with secukinumab for ≥24 weeks Results: Four patients had chronic inactive HBV infection, two patients had occult HBV infection, and the other 14 patients had resolved HBV infection. The HBV- DNA load and HBV markers measured at baseline and Week 24 showed no viral reactivation. Nineteen patients showed normal levels of liver enzymes after 24 weeks of therapy. However, one patient with resolved HBV infection and fatty liver with elevated baseline liver enzymes experienced hepatitis, with negative HBV load at baseline and Week 24. All patients showed a significant improvement in the Psoriasis Area and Severity Index (−13.35 ± 7.41: p < 0.0001), per cent of body surface area (−17.11 ± 17: p = 0.0002), Investigator Global Assessment (−2.55 ± 0.94: p < 0.0001), and Dermatology Life Quality Index (−12.3 ± 7.39; p < 0.0001) Conclusion:
|
Authors | Hui Qin, Na Liu, Yifan Hu, Ning Yu, Xuemei Yi, Yunlu Gao, Fujuan Chen, Jun Gu, Yangfeng Ding, Yuling Shi |
Journal | European journal of dermatology : EJD
(Eur J Dermatol)
Vol. 32
Issue 3
Pg. 394-400
(05 01 2022)
ISSN: 1952-4013 [Electronic] France |
Vernacular Title | Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study. |
PMID | 36065536
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- DNA, Viral
- secukinumab
|
Topics |
- Antibodies, Monoclonal, Humanized
- DNA, Viral
- Hepatitis A
- Hepatitis B virus
- Hepatitis B, Chronic
(complications, drug therapy)
- Humans
- Psoriasis
(complications, drug therapy)
- Retrospective Studies
- Treatment Outcome
|